Multicentric Angiofollicular Lymphoid Hyperplasia
Associated Genetic Biomarkers
NCI Definition: A form of angiofollicular lymphoid hyperplasia characterized by fever, generalized lymphadenopathy, hypergammaglobulinemia, and dysfunction of multiple organs. Other signs and symptoms include anemia, thrombocytopenia, hepatomegaly, peripheral neuropathy and pleural effusions. Morphologically, in the majority of cases the lymph nodes show features of angiofollicular lymphoid hyperplasia of the plasma cell type. In a minority of cases, changes of angiofollicular lymphoid hyperplasia of the hyaline-vascular type are seen. In contrast to patients with localized disease who are usually cured following resection of the lesion, patients with the multicentric form of the disease may follow a progressive clinical course, complicated by infection, Kaposi sarcoma, or lymphoma. 
There are 2 clinical trials for multicentric angiofollicular lymphoid hyperplasia, of which 2 are open and 0 are completed or closed. Of the trials that contain multicentric angiofollicular lymphoid hyperplasia as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
HHV8, KSHV, and MS4A1 are the most frequent gene inclusion criteria for multicentric angiofollicular lymphoid hyperplasia clinical trials .
Rituximab, hyaluronidase, human, and bortezomib are the most common interventions in multicentric angiofollicular lymphoid hyperplasia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.